spacer
home > > summer 2009 > epro excellence
PUBLICATIONS


ePRO Excellence

Clinical trial sponsors can reap many rewards from collecting patient reported outcomes electronically in multinational clinical trials. Advantages include significant improvements in clinic and subject compliance, data quality, data access and monitoring, as well as reduced staff and subject burden. Yet, as many know, ePRO can also present challenges. By understanding some of the important ePRO best practices, however, sponsors can overcome or bypass the major challenges, and then can more easily realise the promises and benefits that ePRO can offer.

BRIEF SUMMARY OF THE CHALLENGES

One of the major challenges a sponsor faces when using ePRO in multinational trials is ensuring the quality and reliability of the ePRO systems and data files. After all, even small problems with the systems or data can sometimes damage credibility, which can lead to decreased system usage, increased enrolment, queries, and other trial costs, and at worst, the discrediting of all the ePRO data.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Joy Hebert is a co-founder and Chief Operating Officer of .assisTek (formerly Assist Technologies), the global leader in ePROs on touch-screen tablets. Joy has worked in healthcare informatics for 30 years. For the last 15 years she has managed the development and implementation of ePRO systems in clinical studies worldwide.
spacer
Joy Hebert
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement